Relovair Data Raises Respiratory Stakes For GSK And Theravance
Executive Summary
Mixed Phase III data results on GSK/Theravance’s once-daily follow-up to Advair raises the regulatory and commercial stakes for the drug, a crucial pipeline product for both companies
You may also be interested in...
COPD Market Snapshot: New Products, Limited Differentiation
New drugs are hitting the COPD market, but largely offer incremental benefit over gold standards Advair and Spiriva. Given the modest efficacy improvement and increasingly price sensitive patients and payers, new higher-priced products may find the commercial market a challenge.
For Theravance, A Big Year Gets Off To A Strong Start
Theravance could soon have its first substantial revenue generator on the market, the COPD therapy Breo Ellipta partnered with GlaxoSmithKline. The launch of Breo is just one of several catalysts expected to unfold for the biotech in 2013.
FDA Panel Will Weigh Mixed Efficacy Data For GSK’s Breo Ellipta In COPD
Agency says data supporting the relative contribution of the combination drug’s corticosteroid component, fluticasone, are “less robust” than data supporting the bronchodilatory effects of the long-acting beta-agonist component, vilanterol.